Bioventus Ownership
| BVS Stock | USD 10.10 0.13 1.30% |
Shares in Circulation | First Issued 2015-03-31 | Previous Quarter 64.1 M | Current Value 65.3 M | Avarage Shares Outstanding 56.4 M | Quarterly Volatility 8.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Bioventus |
Bioventus Stock Ownership Analysis
About 70.0% of the company shares are held by institutions such as insurance companies. The book value of Bioventus was currently reported as 2.28. The company has Price/Earnings To Growth (PEG) ratio of 2.14. Bioventus recorded a loss per share of 0.61. The entity had not issued any dividends in recent years. Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the bodys natural healing process in the United States and internationally. The company was founded in 2011 and is headquartered in Durham, North Carolina. Bioventus Inc operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 1160 people. For more info on Bioventus please contact Kenneth Reali at 919 474 6700 or go to https://www.bioventus.com.Besides selling stocks to institutional investors, Bioventus also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Bioventus' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Bioventus' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Bioventus Quarterly Liabilities And Stockholders Equity |
|
Bioventus Insider Trades History
About 12.0% of Bioventus are currently held by insiders. Unlike Bioventus' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Bioventus' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Bioventus' insider trades
Bioventus Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bioventus is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bioventus backward and forwards among themselves. Bioventus' institutional investor refers to the entity that pools money to purchase Bioventus' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | American Century Companies Inc | 2024-09-30 | 638 K | Ophir Asset Management Pty Ltd | 2024-09-30 | 524.2 K | Oberweis Asset Management Inc | 2024-09-30 | 510.9 K | Millennium Management Llc | 2024-09-30 | 431.6 K | Charles Schwab Investment Management Inc | 2024-09-30 | 390.2 K | Renaissance Technologies Corp | 2024-09-30 | 387.9 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 380.8 K | Segall Bryant & Hamill | 2024-09-30 | 377.8 K | Aqr Capital Management Llc | 2024-09-30 | 366.7 K | Essex Woodlands Health Ventures | 2024-09-30 | 13 M | Juniper Investment Co, Llc | 2024-09-30 | 6.9 M |
Bioventus Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bioventus insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bioventus' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bioventus insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bioventus Outstanding Bonds
Bioventus issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bioventus uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bioventus bonds can be classified according to their maturity, which is the date when Bioventus has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Bioventus Corporate Filings
F4 | 14th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 3rd of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of November 2024 Other Reports | ViewVerify | |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Bioventus Stock Analysis
When running Bioventus' price analysis, check to measure Bioventus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioventus is operating at the current time. Most of Bioventus' value examination focuses on studying past and present price action to predict the probability of Bioventus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioventus' price. Additionally, you may evaluate how the addition of Bioventus to your portfolios can decrease your overall portfolio volatility.